Combination therapies in Myeloproliferative Neoplasms: why do we need them and how to identify potential winners?

Donal McLornan, Claire Harrison*

*Corresponding author for this work

Research output: Contribution to journalComment/debatepeer-review

4 Citations (Scopus)
Original languageEnglish
Pages (from-to)1410-1414
Number of pages5
JournalJOURNAL OF CELLULAR AND MOLECULAR MEDICINE
Volume17
Issue number11
DOIs
Publication statusPublished - Nov 2013

Keywords

  • PROTEIN-KINASE-B
  • REVISED RESPONSE CRITERIA
  • POLYCYTHEMIA-VERA
  • MTOR INHIBITOR
  • JAK2 V617F
  • IWG-MRT
  • CANCER
  • MYELOFIBROSIS
  • ACTIVATION
  • PATHWAY

Cite this